Cost-effectiveness of eptifibatide in NSTEMI patients in Poland

被引：0
|
作者：
Dewilde, S
Opolski, G
Brown, R
机构：
[1] Med Acad, Warsaw, Poland
[2] UBC, MEDTAP Inst, Brussels, Belgium
[3] UBC, MedTap Inst, London, England
来源：
VALUE IN HEALTH | 2005年 / 8卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)67486-4
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A111 / A112
页数：2
相关论文
共 50 条
  • [1] Cost-effectiveness of eptifibatide in patients undergoing percutaneous coronary intervention in Germany
    Dewilde, S.
    Bruggenjurgen, B.
    Welte, R.
    Willich, S. N.
    VALUE IN HEALTH, 2006, 9 (06) : A192 - A192
  • [2] Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
    Dewilde, Sarah
    Brueggenjuergen, Bernd
    Nienaber, Christoph
    Senges, Jochen
    Welte, Robert
    Willich, Stefan N.
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2012, 13 (04): : 381 - 391
  • [3] Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany
    Sarah Dewilde
    Bernd Brüggenjürgen
    Christoph Nienaber
    Jochen Senges
    Robert Welte
    Stefan N. Willich
    The European Journal of Health Economics, 2012, 13 : 381 - 391
  • [4] Cost-effectiveness of eptifibatide in patients undergoing planned coronary stenting: Results from the ESPRIT trial
    Cohen, DJ
    Cosgrove, RS
    Berezin, RH
    O'Shea, J
    Kitt, MM
    Gilchrist, I
    Mark, DB
    Tcheng, JE
    CIRCULATION, 2001, 104 (17) : 386 - 387
  • [5] THE COST-EFFECTIVENESS ANALYSIS OF VARENICLINE FOR SMOKING CESSATION IN POLAND
    Walczak, J.
    Nogas, G.
    Dybek-Karpiuk, A.
    Augustynska, J.
    Stelmachowski, J.
    Garbacka, M.
    Obrzut, G.
    Pawlik, D.
    VALUE IN HEALTH, 2009, 12 (07) : A303 - A303
  • [6] The cost-effectiveness of screening strategies for familial hypercholesterolaemia in Poland
    Pelczarska, Aleksandra
    Jakubczyk, Michal
    Jakubiak-Lasocka, Joanna
    Banach, Maciej
    Mysliwiec, Malgorzata
    Gruchala, Marcin
    Niewada, Maciej
    ATHEROSCLEROSIS, 2018, 270 : 132 - 138
  • [7] The cost-effectiveness analysis of entecavir in the treatment of chronic hepatitis B (CHB) patients in Poland
    Orlewska, E.
    Cerri, K. H.
    Kutikova, L.
    Yuan, Y.
    Iloeje, U.
    Hay, J. W.
    VALUE IN HEALTH, 2007, 10 (03) : A162 - A163
  • [8] Cost-effectiveness of adding leflunomide to standard drug sequences for rheumatoid arthritis patients in Poland
    Golicki, D.
    Niewada, M.
    Lis, J.
    Macioch, T.
    VALUE IN HEALTH, 2007, 10 (06) : A246 - A246
  • [9] Cost, Effectiveness, and Cost-Effectiveness
    Diamond, George A.
    Kaul, Sanjay
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2009, 2 (01): : 49 - 54
  • [10] THE COST-EFFECTIVENESS ANALYSIS OF VIDALGLIPTIN IN TYPE 2 DIABETES IN POLAND
    Walczak, J.
    Nogas, G.
    Gebus, E.
    Pawlik, D.
    Pacocha, K.
    VALUE IN HEALTH, 2009, 12 (07) : A406 - A406
12345